Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Compass Point Downgrades Centerspace to Neutral, Announces $75 Price Target

Compass Point analyst Merrill Ross downgrades Centerspace (NYSE:CSR) from Buy to Neutral and announces $75 price target.
byBenzinga Newsdesk
November 2, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Compass Point analyst Merrill Ross downgrades Centerspace (NYSE:CSR) from Buy to Neutral and announces $75 price target.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca Announced Ultomiris Approved in Europe for the Treatment of Adults with Generalized Myasthenia Gravis

By Charles Gross
September 23, 5:04 AM
Ultomiris (ravulizumab) has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. This decision marks the first and only approval for a long-acting C5 complement inhibitor for

AZN